J. Seigne

Publications149
h-index29
Citations4,221
Highly Influential Citations144
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • H. Herr
  • 671 Publications, 31,569 Citations
  • Y. Lotan
  • 1,059 Publications, 30,761 Citations
  • S. Shariat
  • 1,773 Publications, 46,838 Citations
  • A. Schned
  • 192 Publications, 7,452 Citations
  • Publications
  • Influence
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.
PURPOSE Although associated with an overall favorable survival rate, the heterogeneity of non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and progression. Risk… Expand
  • 433
  • 33
  • PDF
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
M ore than 60,000 new cases of bladder cancer are diagnosed each year in the US accounting for approximately 13,000 deaths annually. When initially diagnosed, most bladder cancers are nonmuscle… Expand
  • 748
  • 29
Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.
Signal transducers and activators of transcription (STATs) were identified originally as key components of cytokine signaling pathways. More recently, constitutive activation of STAT proteins has… Expand
  • 495
  • 15
  • PDF
Treatment decision‐making strategies and influences in patients with localized prostate carcinoma
Patients diagnosed with localized prostate carcinoma need to interpret complicated medical information to make an informed treatment selection from among treatments that have comparable efficacy but… Expand
  • 120
  • 8
The specific role of isoflavones in reducing prostate cancer risk
To evaluate the effectiveness of supplementing a group of early stage prostate cancer patients, with 60 mg of soy isoflavones in producing a change in hormonal and proliferative risk parameters that… Expand
  • 148
  • 6
Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN-α2a Therapy in Metastatic Renal Cell Carcinoma Patients
Purpose: To evaluate the clinical and immunologic outcomes of DC (dendritic cell) vaccine with interleukin (IL)-2 and IFN-α 2a in metastatic renal cell carcinoma patients. Experimental Design:… Expand
  • 84
  • 6
Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer.
PURPOSE An amino acid changing polymorphism in the UDP-glucuronosyltransferase (UGT) 2B15 gene has been described at codon 85 (aspartate>tyrosine). The UGT2B15 allele exhibits 2-fold decreased… Expand
  • 76
  • 5
MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer
BackgroundMicroRNAs have been identified as potential cancer biomarkers due to their presence and stability in many body fluids including urine and plasma, but the relationship of the pattern of… Expand
  • 106
  • 4
YouTube as source of prostate cancer information.
OBJECTIVES Patients can search the Internet for prostate cancer information, and YouTube is a popular Web site that they may consult. We analyzed the prostate cancer videos on YouTube for information… Expand
  • 166
  • 3
Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein.
The preclinical studies presented here demonstrate that treatment of human non-small cell lung carcinoma and bladder carcinoma cells by a recombinant adenovirus vector, AdCMVpRB94, expressing the… Expand
  • 108
  • 3
  • PDF